Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Eisai Co., Ltd.
  6. Summary
    4523   JP3160400002

EISAI CO., LTD.

(4523)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Japan Exchange
07/15/2021 07/16/2021 07/19/2021 07/20/2021 07/21/2021 Date
10520 9157 9268 9259 9141 Last
860000 7569600 5469300 2314200 2426800 Volume
-1.59% -12.96% +1.21% -0.10% -1.27% Change
Estimated financial data (e)
Sales 2022 700 B 6 340 M 6 340 M
Net income 2022 59 105 M 536 M 536 M
Net cash position 2022 147 B 1 331 M 1 331 M
P/E ratio 2022 44,3x
Yield 2022 1,77%
Sales 2023 736 B 6 665 M 6 665 M
Net income 2023 61 729 M 559 M 559 M
Net cash position 2023 156 B 1 413 M 1 413 M
P/E ratio 2023 42,4x
Yield 2023 1,88%
Capitalization 2 620 B 23 708 M 23 744 M
EV / Sales 2022 3,54x
EV / Sales 2023 3,35x
Nbr of Employees 11 237
Free-Float 87,5%
More Financials
Company
Eisai Co., Ltd. is a Japan-based pharmaceutical company mainly engaged in the research and development, manufacture, sale, import and export of pharmaceuticals. The Company operates in two business segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sale of pharmaceuticals for medical use, generic drugs, general medicines, among others. The segment operates in five regions... 
Sector
Pharmaceuticals
Calendar
08/04Earnings Release
More about the company
Ratings of Eisai Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about EISAI CO., LTD.
07/23MERCK : FDA Approves KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) Combinat..
AQ
07/22EISAI : FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combinat..
AQ
07/21Eisai to present latest data on pipeline assets in the area of alzheimer's di..
AQ
07/21BIOGEN : Alzheimer's drug slow to take off as U.S. Medicare wrestles with covera..
RE
07/20EISAI : to Present Latest Data on Pipeline Assets in The Area of Alzheimer's Dis..
AQ
07/19EISAI : Status of aduhelm in the united states
AQ
07/18EISAI : Launchs Bile Acid Transporter Inhibitor Goofice in Thailand
AQ
07/16Nikkei dips below 28,000 as tech stocks track Nasdaq slide
RE
07/15Nikkei breaks below 28,000 as tech stocks track Nasdaq slide
RE
07/12Japanese shares rebound on growth confidence, Yaskawa's outlook
RE
07/09BIOGEN : FDA Approves Updated ADUHELM Prescribing Information to Emphasize Popul..
AQ
07/09Japanese shares fall to 8-week low on growth slowdown worries
RE
07/09BIOARCTIC : Interim Report for the period April - June 2021
AQ
07/08Japanese shares eye worst week in nearly 1 year on economic slowdown concerns
RE
07/08BIOGEN : Eisai Receives FDA Approval for Updated Label of Alzheimer's Drug Aduhe..
MT
More news
News in other languages on EISAI CO., LTD.
07/16MÄRKTE ASIEN/Mehrheitlich Abgaben - Technologiewerte unter Druck
07/16Tokyo toujours perturbée par la situation sanitaire au Japon
07/16MÄRKTE ASIEN/Mehrheitlich Abgaben - Technologiewerte geben nach
06/25MÄRKTE ASIEN/Konjunkturzuversicht treibt Aktienkurse
06/25MÄRKTE ASIEN/Börsen folgen US-Vorgaben nach oben
More news
Analyst Recommendations on EISAI CO., LTD.
More recommendations
Chart EISAI CO., LTD.
Duration : Period :
Eisai Co., Ltd. Technical Analysis Chart | 4523 | JP3160400002 | MarketScreener
Technical analysis trends EISAI CO., LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 13
Last Close Price 9 141,00 JPY
Average target price 12 439,23 JPY
Spread / Average Target 36,1%
EPS Revisions
Managers and Directors
Haruo Naito Chief Executive Officer & Representative Director
Ryohei Yanagi Chief Financial Officer
Yasuhiko Katoh Chairman
Edward Stewart Geary Chief Medical Officer & Managing Executive Officer
Lynn D. Kramer Chief Medical & Chief Clinical Officer-Neurology
Sector and Competitors
1st jan.Capi. (M$)
EISAI CO., LTD.24.00%30 450
JOHNSON & JOHNSON9.16%432 430
ROCHE HOLDING AG12.39%325 975
PFIZER, INC.13.23%218 198
ELI LILLY AND COMPANY44.60%209 276
NOVARTIS AG1.10%207 246